Transcriptional effects of copy number alterations in a large set of human cancers

Link to paper Bhattacharya A, Bense RD, Urzúa-Traslaviña CG, de Vries EGE, van Vugt MATM, Fehrmann RSN AbstractCopy number alterations (CNAs) can promote tumor progression by altering gene expression levels. Due to transcriptional adaptive mechanisms, however, CNAs do not always translate proportionally into altered expression levels. By reanalyzing >34,000 gene expression profiles, we reveal the…

Driving innovation for rare skin cancers: utilising common tumours and machine learning to predict immune checkpoint inhibitor response

Link to paper J.S. Hooiveld-Noeken, R.S.N. Fehrmann, E.G.E. de Vries, M. Jalving Highlights • Metastatic Merkel- and cutaneous squamous cell carcinoma are rare tumours. • Immunotherapy gives impressive responses but most patients do not survive long-term. • Small patients numbers prevent extensive biomarker research in clinical trials. • Pooled data from common and rare tumours…

Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers

Link to paper Peters MAM, Meijer C, Fehrmann RSN, Walenkamp AME, Kema IP, de Vries EGE, Hollema H, Oosting SF. Abstract In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set…

CD47 expression defines efficacy of rituximab with CHOP in Non-Germinal Center B-cell (non-GCB) Diffuse Large B-Cell Lymphoma patients (DLBCL), but not in GCB DLBCL

Link to paper Bouwstra R, He Y, de Boer JW, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T. Abstract Addition of rituximab (R) to “CHOP” (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients that…

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6)

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5545-0 Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt- Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann…

APK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells

https://onlinelibrary.wiley.com/doi/abs/10.1002/path.5280 Stutvoet TS, Kol A, de Vries EGE, de Bruyn M, Fehrmann RSN, Terwisscha van Scheltinga AGT, de Jong S. Abstract Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with non‐small cell lung cancer (NSCLC). Still, many patients do not respond to…

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

http://clincancerres.aacrjournals.org/content/early/2019/02/09/1078-0432.CCR-18-2918.long Moek KL, Waaijer SJH, Kok IC, Suurs FV, Brouwers AH, Menke-van der Houven van Oordt CW, Wind TT, Gietema JA, Schröder CP, Mahesh SVK, Jorritsma-Smit A, Lub-de Hooge MN, Fehrmann RSN, de Groot DJ, de Vries EG. ABSTRACTPurpose: Biodistribution of bispecific antibodies in patients is largely unknown. We therefore performed a feasibility study in nine…